The Management of Metastatic Neck Nodes in N2/3 Hypopharyngeal Squamous Cell Carcinoma

Inclusion Criteria:

1. Able to understand and willing to sign a written informed consent document.

2. Age ≥ 18 and ≤ 75 years.

3. Male or female.

4. Karnofsky physical status (KPS): ≥ 80

5. Hepatic function, renal function and normal blood test. Hepatic function: Alanineaminotransferase (ALT) ≤ 2.5 upper limit of normal, Aspartate aminotransferase (AST) ≤ 2.5 upper limit of normal. Serum total bilirubin ≤ 1.5 upper limit of normal.Kidney function: Serum creatinine < upper limit of normal value and creatinineclearance rate > 60 ml/(min*1.73m2) (Cockcroft-Gault formula). Blood test:neutrophil (Neu) ≥ 1.5×109/L, platelet (PLT) ≥ 100×109/L, hemoglobin (HGB) ≥ 90 g/L.

6. Pathologically diagnosed with squamous cell carcinoma of the hypopharynx.

7. After clinical and radiographic evaluations, clinically classified as T1/2 N2/3 M0stage according to American Joint Committee on Cancer (AJCC, eighth edition).

8. Resectable regional metastatic lesion (incompletely tumor- wrapped carotidvascular).

9. Assessable tumor lesions according to Response Evaluation Criteria in Solid Tumors (RECIST, Version 1.1).

10. Radical treatment intent.

11. Male patients with fertility and female patients with fertility and pregnancy riskmust agree to use contraceptive methods throughout the study period, and continueduntil at least 6 months after the last dose of cisplatin. Female patients who do nothave fertility (ie meet at least one of the following criteria): Have undergonehysterectomy and/or bilateral oophorectomy with archival records, medicallyconfirmed ovarian function decline; In postmenopausal state. It is defined as: Atleast 12 months of continuous menstruation without other pathological orphysiological reasons, and the status confirmed by serum follicle stimulatinghormone (FSH) levels is consistent with postmenopausal status.

12. Good compliance.

Exclusion Criteria:

1. Distant metastatic disease

2. Have a history of other cancers or coinstantaneous second primary tumor

3. Previous treatment for the primary tumor, including radiotherapy, surgery exceptbiopsy operation, chemotherapy, immunotherapy and biological targeted therapy.

4. Patients who have participated in other clinical trials within 1 month before thetest.

5. Patients estimated to have poor tolerance to induction chemotherapy.

6. The investigator believes that it is inappropriate for individuals to participate inthe trial: having, for example, severe acute or chronic medical conditions (including immune colitis, inflammatory bowel disease, non-infectious pneumonia,pulmonary fibrosis) or mental illness (including recent time [within the past year]or active suicidal ideation or behavior).

7. Palliative treatment intent.

8. Pregnant or lactating women.